This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CRMD003
Neutrolin is an antimicrobial/anticoagulant solution containing taurolidine, citrate and heparin, for filling or locking a central venous catheter (CVC) while it is not being used. Neutrolin is being developed for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients.
Heparin is an approved factor X and thrombin inhibitor. Citrate is used in the formulation of a number of drugs, but at high concentrations is also an anticoagulant that works by binding calcium, preventing its use in the coagulation cascade.
Taurolidine is an antimicrobial agent derived from taurine. Its methylol-containing moieties appear to react with bacterial cell wall components to prevent the adherence of microorganisms to biological surfaces.
CorMedix and Wonik
In August 2014, CorMedix announced a strategic business collaboration with Wonik Corporation, a South Korean corporation with a medical device franchise within the Korean healthcare market. Wonik will market, sell and distribute Neutrolin for hemodialysis patients upon receipt of regulatory approval in Korea.
CorMedix and Arabian Trade House
In December 2014, CorMedix announced a signed Middle East sales/distribution agreement for Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia.
Additional information available to subscribers only: